Shoab Nazir, MD
Pulmonary Disease · Oklahoma City, OKNPI 1992895478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 576 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,096, 4.4 times the $697 reported in 2019.
Across 576 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$581
- Mylan Specialty L.p.$538
- Insmed, Inc.$499
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,83196%
- Education$4104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 94 | $2,294 |
| GSK | 119 | $1,648 |
| Boehringer Ingelheim | 63 | $1,280 |
| Jazz Pharmaceuticals Inc. | 14 | $581 |
| Mylan Specialty L.p. | 42 | $538 |
| Insmed, Inc. | 24 | $499 |
| Amgen | 26 | $496 |
| Actelion Pharmaceuticals US, Inc. | 15 | $418 |
| United Therapeutics Corporation | 18 | $407 |
| Regeneron Healthcare Solutions, Inc. | 17 | $369 |
| Harmony Biosciences LLC | 18 | $358 |
| Pulmonx Corporation | 4 | $315 |
| Sanofi | 15 | $261 |
| Inogen, Inc. | 14 | $182 |
| Inspire Medical Systems, Inc. | 3 | $167 |
| Sunovion Pharmaceuticals Inc. | 22 | $160 |
| Baxter Healthcare | 10 | $160 |
| Viatris Specialty LLC | 15 | $156 |
| Genentech USA, Inc. | 12 | $155 |
| Merck | 7 | $151 |
| Angiodynamics, Inc. | 1 | $147 |
| Philips North America LLC | 7 | $126 |
| Lilly USA, LLC | 4 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Abbott | 1 | $25 |
| Edwards Lifesciences | 1 | $25 |
| Novartis | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,241 in reported general payments places this provider in the 80th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 269 | $3,543,059 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 731 | $931,815 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 375 | $453,204 |
| Spiriva RespimatTiotropium Bromide | 248 | $220,495 |
| Breo ElliptaFluticasone/Vilanterol | 246 | $171,294 |
| EsbrietPirfenidone | 12 | $95,977 |
| Pirfenidone | 29 | $60,698 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 94 | $59,252 |
| Dupixent PenDupilumab | 16 | $58,535 |
| EliquisApixaban | 35 | $44,099 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $43,839 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 824 | $36,034 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $33,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 138 | $26,013 |
| Incruse ElliptaUmeclidinium Bromide | 52 | $25,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,280 | $3,827,672588 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,648 | $1,187,8161,123 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,294 | $486,767451 claims |
| Genentech USA, Inc.Esbriet | $155 | $95,97712 claims |
| MerckDulera | $151 | $6,76718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
- Azhar KhanOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.